Sigumir (Cartalax) — cartilage / joint bioregulator

Sigumir is the cytomedin (tissue-extract) form and Cartalax is the synthetic short-peptide form of the Khavinson cartilage / joint bioregulator. Both are commercially available as supplements in the Khavinson product portfolio.

Sigumir is the cytomedin branch (cartilage tissue extract) and Cartalax is the more recent short-peptide branch of the Khavinson cartilage / joint bioregulator family. Both are positioned as joint-tissue regulators within the broader bioregulator framework. They are often discussed together in the user-community literature.

Within the Khavinson framework, both forms are proposed to support cartilage and joint tissue regenerative function through tissue-specific regulatory signaling. Independent Western validation is limited.^[1]

Sigumir as a cytomedin is mixture-based; Cartalax as a defined short peptide has very short systemic half-life. Both are administered orally in commercial form.

The peer-reviewed literature on Sigumir is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

Both forms are typically administered orally as capsules in cyclic regimens consistent with the Khavinson product line.

Sigumir / Cartalax represents the joint-tissue arm of the Khavinson bioregulator framework. For readers interested in the broader concept of tissue-specific peptide bioregulation, this pair is an entry point. For osteoarthritis-specific therapy, the mainstream evidence-graded options (NSAIDs, physical therapy, viscosupplementation, the emerging biologics) sit on a different evidence tier.